

Mar. 24, 2014 - WORCESTER, Mass. -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced its publication in the journal *Pharmaceutical Research* which supports the scientific rationale for Nemucore's ongoing NMI-300 development program. The Paper, titled "*Development Of EGFR Targeted Nanoemulsion For Imaging And Novel Platinum Therapy Of Ovarian Cancer*" was co-authored by NMI's Niravkumar Patel, Barbara Davis, Joseph Cacaccio, and Timothy Coleman.

Platinum-based chemotherapy is the treatment of choice for malignant epithelial ovarian cancers, but generalized toxicity and platinum resistance limits its use. NMI is designing a novel targeted nanomedicine platinum prodrug, myrisplatin, and a proapoptotic agent, were designed to overcome limitations associated with treating multidrug resistant cancers. The study results demonstrate this novel nanomedicine synergistically enhanced cytotoxicity of platinum in cultured cancer cells and that this cytotoxicity was significantly enhanced for EGFR positive cancer cells.

Nemucore's lead compound is NMI-300, a personalized nanomedicine targets ovarian cancer expressing epidermal growth factor receptor (EGFR), a cell-surface receptor overexpressed in certain ovarian cancers. EGFR overexpression in cancer cells is implicated in disease aggressiveness and drug resistance.

"These findings provide strong evidence for the value of targeted nanoemulsions," said Timothy Coleman, Ph.D. Nemucore's CEO "Collectively, this data further supports the focus on nanoemulsions as the future of personalized medicines. These nanomedicines have interesting physical properties that can be exploited to overcome anatomical and physiological barriers associated in drug delivery to the complex diseases such as cancer."

"The ongoing development of these nanomedicines is with the clinic in mind," said Dr. Barbara Davis, Nemucore's CSO. "These studies contribute to our understanding of how to design nanomedicines with attributes to treat multidrug resistant cancers."

Nemucore is currently pushing towards bringing these nanomedicines to the clinic.

About Ovarian Cancer

In the U.S., approximately 80,000 women are diagnosed with some form of

gynecological cancer (cervical, ovarian, uterine, vaginal, and vulvar) with approximately 27,000 deaths annually. Of these 80,000 gynecological cancers diagnosed annually, an estimated 22,000 new ovarian cancer cases are diagnosed alongside approximately 15,000 deaths in the U.S., making epithelial ovarian cancer the most lethal of gynecologic cancers.

About Nemucore Medical Innovations, Inc.

NMI is dedicated to designing, investigating, developing, and commercializing life-saving novel nanomedicines for the treatment of ovarian cancer and other unmet medical needs. Ultimately, NMI's products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit <http://www.nemucore.com>.

Forward-looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

